Clinical trials

• Patients with unresectable stage 3 pancreatic ductal adenocarcinoma
• Newly diagnosed and has only received single line of chemotherapy (mFOLFIRINOX or gemcitabine-based) for at least 3 months but no more than 6 months prior to enrolment
• Maximum axial tumour dimension of ≤3.5cm after receiving 3 to 6 months of chemotherapy

Exclusion:

• Have evidence of disease progression
• Have undergone radiation therapy/surgical resection/IRE treatment
• Patients with implanted cardiac pacemakers, defibrillators or any electronic/implanted devices with metal parts in the thoracic cavity at time of IRE
• Patients with history of epilepsy or other neurological disease

CEND-1 is a novel cyclic tumour‐penetrating peptide iRGD (internalising Arginylglycylaspartic acid) which may overcome poor drug delivery by increasing vascular permeability of tumour vessels to treatment.

• Metastatic pancreatic cancer suitable for first-line gemcitabine and nab-paclitaxel chemotherapy
• ECOG 0 or 1

• Advanced pancreatic adenocarcinoma (metastatic or locally advanced)
• Eligible for treatment with nab-paclitaxel and gemcitabine as standard of care therapy
• ECOG 0 or 1

• Disease must have progressed after one line of standard fluoropyrimidine- or gemcitabine-based chemotherapy for advanced disease. Treatment break within the upfront chemotherapy regimen is considered the same line of therapy and is permitted.
• One line of systemic therapy for advanced disease. Patients who have had two lines of systemic therapy or are intolerant of second-line treatment may be eligible after consultation with the study Chief Investigators.

Exclusion:

• Uncontrolled diabetes (HbA1c>10% in previous 3 weeks)
• Uncontrolled hypertension (SBP>180mmHg or DBP>105mmHg)
• NYHA Class III or IV heart failure 
• Major surgery OR radiation therapy OR participation in other investigational products within 28 days prior to commencement of this study